Loading...
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
IMPORTANCE: Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited. OBJECTIVE: To evaluate the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor niraparib combined with pembrolizumab in patie...
Na minha lista:
| Udgivet i: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Medical Association
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6567832/ https://ncbi.nlm.nih.gov/pubmed/31194228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1048 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|